What is your preferred approach to third-line treatment of metastatic HER2 positive esophageal adenocarcinoma after progression on FOLFOX/CAPOX + trastuzumab, then T-DXd?

PD-L1 CPS of 1, no other actionable mutations except HER2.

2 Answers

Mednet MemberInvited Expert

Medical Oncology · Memorial Sloan Kettering Cancer Center

Answered on

If the patient's disease is still HER2+, I would strongly consider a clinical trial. Outside of a trial, my preferred 3L therapy would be ramucirumab/paclitaxel. The phase 3 RAINBOW trial (Wilke et al., PMID 25240821) showed a survival benefit of ram/paclitaxel over paclitaxel alone. In this trial, 8-9% of patients had prior treatment of "HER2, EGFR, or other".

Subsequent analyses have showed that ram/paclitaxel is active regardless of HER2 status (Kim et al., PMID 35015188 and Valcarcel et al., PMID 36042046).

Mednet MemberInvited Expert

Medical Oncology · Rutgers Cancer Institute of New Jersey

Answered on

I lean toward FOLFIRI rather than taxane-based regimens as it appears to be quite active. There are numerous phase 2 studies, just no large phase 3 due to lack in sponsor interest. Also, trifluridine/tiperacil (TAS-102) is an option here.